Diethylcarbamazine in the control of bancroftian filariasis in the Ok Tedi area of Papua New Guinea: phase 2--annual single-dose treatment.
Identifieur interne : 005546 ( PubMed/Corpus ); précédent : 005545; suivant : 005547Diethylcarbamazine in the control of bancroftian filariasis in the Ok Tedi area of Papua New Guinea: phase 2--annual single-dose treatment.
Auteurs : G J Schuurkamp ; R K Kereu ; P K Bulungol ; A. Kawereng ; P E SpicerSource :
- Papua and New Guinea medical journal [ 0031-1480 ] ; 1994.
English descriptors
- KwdEn :
- Adolescent, Adult, Animals, Child, Child, Preschool, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (therapeutic use), Drug Administration Schedule, Elephantiasis, Filarial (complications), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (parasitology), Humans, Malaria (epidemiology), Middle Aged, Papua New Guinea (epidemiology), Splenomegaly (parasitology), Treatment Outcome, Wuchereria bancrofti.
- MESH :
- chemical , administration & dosage : Diethylcarbamazine.
- chemical , therapeutic use : Diethylcarbamazine.
- geographic , epidemiology : Papua New Guinea.
- complications : Elephantiasis, Filarial.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial, Malaria.
- parasitology : Elephantiasis, Filarial, Splenomegaly.
- Adolescent, Adult, Animals, Child, Child, Preschool, Drug Administration Schedule, Humans, Middle Aged, Treatment Outcome, Wuchereria bancrofti.
Abstract
The Phase 1 semiannual single-dose 6 mg/kg diethylcarbamazine (DEC) treatment program demonstrated a significant reduction for Wuchereria bancrofti in the Ok Tedi area of Western Province, Papua New Guinea. The rate of detectable microfilaraemia was effectively reduced from 39% to 11% and mean microfilarial (mf) densities from 79mf/20 microliters to 19mf/20 microliters. The Phase 2 annual single-dose treatment of 6mg/kg DEC not only maintained the gains made during Phase 1 but reduced the microfilaraemia rate to less than 5% by 1990, with mf densities remaining stable at less than 20mf/20 microliters, amongst all participating villagers screened within the 5 original villages. The annual treatment program was expanded into 7 remote villages not subject to any form of active vector control. The microfilaraemia rate in these villages declined from 41% before treatment to 17% after only two annual administrations of 6mg/kg DEC, and mf blood densities were reduced from 71mf/20 microliters to 20mf/20 microliters. As was observed in the 5 original villages participating in the program, a significant reduction in splenomegaly associated with the DEC treatment was reported for the 7 villages in the expanded program during Phase 2; enlarged spleen rates were reduced from 50% (1986) to 32% (1990) and from 76% (1988) to 48% (1990), respectively. Malaria rates on the other hand increased slightly or remained stable. Malaria infections associated with W. bancrofti (mixed parasite infections) stimulated a greater splenic response than either parasite detected on its own.
PubMed: 7771117
Links to Exploration step
pubmed:7771117Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diethylcarbamazine in the control of bancroftian filariasis in the Ok Tedi area of Papua New Guinea: phase 2--annual single-dose treatment.</title><author><name sortKey="Schuurkamp, G J" sort="Schuurkamp, G J" uniqKey="Schuurkamp G" first="G J" last="Schuurkamp">G J Schuurkamp</name><affiliation><nlm:affiliation>Medical Department, Ok Tedi Mining Limited, Tabubil, Papua New Guinea.</nlm:affiliation></affiliation></author><author><name sortKey="Kereu, R K" sort="Kereu, R K" uniqKey="Kereu R" first="R K" last="Kereu">R K Kereu</name></author><author><name sortKey="Bulungol, P K" sort="Bulungol, P K" uniqKey="Bulungol P" first="P K" last="Bulungol">P K Bulungol</name></author><author><name sortKey="Kawereng, A" sort="Kawereng, A" uniqKey="Kawereng A" first="A" last="Kawereng">A. Kawereng</name></author><author><name sortKey="Spicer, P E" sort="Spicer, P E" uniqKey="Spicer P" first="P E" last="Spicer">P E Spicer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7771117</idno><idno type="pmid">7771117</idno><idno type="wicri:Area/PubMed/Corpus">005546</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005546</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Diethylcarbamazine in the control of bancroftian filariasis in the Ok Tedi area of Papua New Guinea: phase 2--annual single-dose treatment.</title><author><name sortKey="Schuurkamp, G J" sort="Schuurkamp, G J" uniqKey="Schuurkamp G" first="G J" last="Schuurkamp">G J Schuurkamp</name><affiliation><nlm:affiliation>Medical Department, Ok Tedi Mining Limited, Tabubil, Papua New Guinea.</nlm:affiliation></affiliation></author><author><name sortKey="Kereu, R K" sort="Kereu, R K" uniqKey="Kereu R" first="R K" last="Kereu">R K Kereu</name></author><author><name sortKey="Bulungol, P K" sort="Bulungol, P K" uniqKey="Bulungol P" first="P K" last="Bulungol">P K Bulungol</name></author><author><name sortKey="Kawereng, A" sort="Kawereng, A" uniqKey="Kawereng A" first="A" last="Kawereng">A. Kawereng</name></author><author><name sortKey="Spicer, P E" sort="Spicer, P E" uniqKey="Spicer P" first="P E" last="Spicer">P E Spicer</name></author></analytic><series><title level="j">Papua and New Guinea medical journal</title><idno type="ISSN">0031-1480</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Drug Administration Schedule</term><term>Elephantiasis, Filarial (complications)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (parasitology)</term><term>Humans</term><term>Malaria (epidemiology)</term><term>Middle Aged</term><term>Papua New Guinea (epidemiology)</term><term>Splenomegaly (parasitology)</term><term>Treatment Outcome</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Papua New Guinea</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Malaria</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Splenomegaly</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Drug Administration Schedule</term><term>Humans</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Phase 1 semiannual single-dose 6 mg/kg diethylcarbamazine (DEC) treatment program demonstrated a significant reduction for Wuchereria bancrofti in the Ok Tedi area of Western Province, Papua New Guinea. The rate of detectable microfilaraemia was effectively reduced from 39% to 11% and mean microfilarial (mf) densities from 79mf/20 microliters to 19mf/20 microliters. The Phase 2 annual single-dose treatment of 6mg/kg DEC not only maintained the gains made during Phase 1 but reduced the microfilaraemia rate to less than 5% by 1990, with mf densities remaining stable at less than 20mf/20 microliters, amongst all participating villagers screened within the 5 original villages. The annual treatment program was expanded into 7 remote villages not subject to any form of active vector control. The microfilaraemia rate in these villages declined from 41% before treatment to 17% after only two annual administrations of 6mg/kg DEC, and mf blood densities were reduced from 71mf/20 microliters to 20mf/20 microliters. As was observed in the 5 original villages participating in the program, a significant reduction in splenomegaly associated with the DEC treatment was reported for the 7 villages in the expanded program during Phase 2; enlarged spleen rates were reduced from 50% (1986) to 32% (1990) and from 76% (1988) to 48% (1990), respectively. Malaria rates on the other hand increased slightly or remained stable. Malaria infections associated with W. bancrofti (mixed parasite infections) stimulated a greater splenic response than either parasite detected on its own.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7771117</PMID><DateCreated><Year>1995</Year><Month>06</Month><Day>30</Day></DateCreated><DateCompleted><Year>1995</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0031-1480</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>1994</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Papua and New Guinea medical journal</Title><ISOAbbreviation>P N G Med J</ISOAbbreviation></Journal><ArticleTitle>Diethylcarbamazine in the control of bancroftian filariasis in the Ok Tedi area of Papua New Guinea: phase 2--annual single-dose treatment.</ArticleTitle><Pagination><MedlinePgn>65-81</MedlinePgn></Pagination><Abstract><AbstractText>The Phase 1 semiannual single-dose 6 mg/kg diethylcarbamazine (DEC) treatment program demonstrated a significant reduction for Wuchereria bancrofti in the Ok Tedi area of Western Province, Papua New Guinea. The rate of detectable microfilaraemia was effectively reduced from 39% to 11% and mean microfilarial (mf) densities from 79mf/20 microliters to 19mf/20 microliters. The Phase 2 annual single-dose treatment of 6mg/kg DEC not only maintained the gains made during Phase 1 but reduced the microfilaraemia rate to less than 5% by 1990, with mf densities remaining stable at less than 20mf/20 microliters, amongst all participating villagers screened within the 5 original villages. The annual treatment program was expanded into 7 remote villages not subject to any form of active vector control. The microfilaraemia rate in these villages declined from 41% before treatment to 17% after only two annual administrations of 6mg/kg DEC, and mf blood densities were reduced from 71mf/20 microliters to 20mf/20 microliters. As was observed in the 5 original villages participating in the program, a significant reduction in splenomegaly associated with the DEC treatment was reported for the 7 villages in the expanded program during Phase 2; enlarged spleen rates were reduced from 50% (1986) to 32% (1990) and from 76% (1988) to 48% (1990), respectively. Malaria rates on the other hand increased slightly or remained stable. Malaria infections associated with W. bancrofti (mixed parasite infections) stimulated a greater splenic response than either parasite detected on its own.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuurkamp</LastName><ForeName>G J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Medical Department, Ok Tedi Mining Limited, Tabubil, Papua New Guinea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kereu</LastName><ForeName>R K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Bulungol</LastName><ForeName>P K</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Kawereng</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Spicer</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Papua New Guinea</Country><MedlineTA>P N G Med J</MedlineTA><NlmUniqueID>0376417</NlmUniqueID><ISSNLinking>0031-1480</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008288" MajorTopicYN="N">Malaria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010219" MajorTopicYN="N" Type="Geographic">Papua New Guinea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013163" MajorTopicYN="N">Splenomegaly</DescriptorName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="Y">Wuchereria bancrofti</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7771117</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005546 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 005546 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:7771117
|texte= Diethylcarbamazine in the control of bancroftian filariasis in the Ok Tedi area of Papua New Guinea: phase 2--annual single-dose treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7771117" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |